angioblast


Also found in: Medical, Wikipedia.

angioblast

[′an·jē·ə‚blast]
(embryology)
A mesenchyme cell derived from extraembryonic endoderm that differentiates into embryonic blood cells and endothelium.
References in periodicals archive ?
Acquired 100% of Angioblast and entire intellectual property for MPCs
12 May 2010 - Australian biotechnology company Mesoblast Limited (ASX: MSB) said today it plans to purchase the 67% stake it does not already own in US sector player Angioblast Systems Inc in a bid to expand its portfolio.
Articles then review strategies for cell delivery, clinical trials, therapies such as whole bone marrow transplantation, clinical angioblast therapy and the use of skeletal myoblasts and other techniques, and the future of the field.
Angioblast and Mesoblast are conducting a Pilot Clinical Trial in Australia focused on the treatment of up to 10 patients suffering from severe coronary artery disease and heart muscle damage.
Hemangiomas may preferentially locate in this soil that seems to favor angioblast migration," said Dr.
But in the rats given angioblast injections, left ventricular function improved by 30% within 15 weeks of treatment, compared to control rats injected with saline.
Melbourne, Australia, Dec 23, 2010 - (ABN Newswire) - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it had completed its acquisition of United States company Angioblast Systems Inc with the issue of 90.
He was chairman of the Board of AtCor Medical and has served as Director on the Boards of Angioblast Systems and Sunshine Heart.
Mesoblast also advises that it has finalized the acquisition of its United States associate company, Angioblast Systems Inc.
We are finalizing a major strategic acquisition of our United States associate company, Angioblast Systems, that will enable Mesoblast shareholders to enjoy all the commercial benefits of the unique technology platform
Melbourne, Australia, Nov 19, 2010 - (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the required period for any antitrust objection under the United States Hart-Scott-Rodino(HSR) anti-trust improvement Act 1976 in respect of its acquisition of Angioblast Systems Inc.
Melbourne, Australia, Nov 8, 2010 - (ABN Newswire) - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (USOTC:MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded $1.